Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Completes $7.79 Million Private Placement
LEXINGTON, Mass. , Jan. 15, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the closing of its previously announced $7.79 million private
View HTML
Toggle Summary Aldeyra Therapeutics Announces $7.79 Million Private Placement
LEXINGTON, Mass. , Jan. 13, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement to raise
View HTML
Toggle Summary Aldeyra Therapeutics Submits IND Filing to FDA for Clinical Testing of NS2 in Patients With Sjogren-Larsson Syndrome
LEXINGTON, Mass. , Jan. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that an Investigational New Drug application (IND) to conduct Phase 2
View HTML
Toggle Summary Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis
LEXINGTON, Mass. , Dec. 18, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that an Investigational New Drug application (IND) to conduct Phase 2
View HTML
Toggle Summary Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting
Novel Anti-Inflammatory Data Selected for Late-Breaking Poster Presentation
View HTML
Toggle Summary Aldeyra Therapeutics Announces Collaboration With the National Organization for Rare Disorders to Enhance Awareness for Sjogren-Larsson Syndrome Patients
LEXINGTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will collaborate with the National Organization for Rare
View HTML
Toggle Summary Aldeyra Therapeutics to Present at the Therapeutic Area Partnerships Meeting
Company Chosen as "Top Projects to Watch" in the Anti-Inflammatory/Autoimmune Industry
View HTML
Toggle Summary Aldeyra Therapeutics Reports Third Quarter and Year to Date 2014 Financial Results
LEXINGTON, Mass. , Nov. 10, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the third quarter and nine months ended
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
BURLINGTON, Mass. , Nov. 3, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the third quarter and the
View HTML
Toggle Summary Aldeyra Therapeutics to Present at Upcoming Investor Conferences
BURLINGTON, Mass., Sept. 5, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will
View HTML